Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.（ACRS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ACRS · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Aclaris Therapeutics, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ACRS 季度内部人买卖趋势
ACRS 内幕交易卖出 · ACRS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ACRS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ACRS 高管卖出股份 · ACRS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 5, 2026 | Mehra Anand Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | SCHIFF ANDREW N Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | Molineaux Christopher P. Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | Humphries William D. Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | MILANO VINCENT Director | Option | 11,580 | — | Form 4 |
| Jun 5, 2026 | GOWEN MAXINE Director | Option | 11,580 | — | Form 4 |
| May 1, 2026 | Hall Jesse Wayne Chief Medical Officer | Option | 36,375 | — | Form 4 |
| May 1, 2026 | Hall Jesse Wayne Chief Medical Officer | Other | 9,330 | $41K | Form 4 |
| Apr 23, 2026 | Leonard Braden Michael 10 percent owner | Sale | 300,000 | $1.36M⚡ | Form 4 |
| Mar 1, 2026 | Balthaser Kevin CFO | Option | 2,375 | — | Form 4 |
| Mar 1, 2026 | Balthaser Kevin CFO | Other | 677 | $2K | Form 4 |
| Feb 3, 2026 | Loerop James Chief Business Officer | Option | 20,875 | — | Form 4 |
| Feb 3, 2026 | Loerop James Chief Business Officer | Other | 5,937 | $21K | Form 4 |
| Feb 3, 2026 | Walker Neal CEO · Director | Option | 63,475 | — | Form 4 |
| Feb 3, 2026 | Walker Neal CEO · Director | Other | 18,611 | $65K | Form 4 |
| Feb 3, 2026 | Davis Hugh M. President and COO · Director | Option | 18,675 | — | Form 4 |
| Feb 3, 2026 | Balthaser Kevin CFO | Option | 22,025 | — | Form 4 |
| Feb 3, 2026 | Balthaser Kevin CFO | Other | 6,449 | $22K | Form 4 |
| Feb 1, 2026 | Balthaser Kevin CFO | Option | 14,750 | — | Form 4 |
| Feb 1, 2026 | Balthaser Kevin CFO | Other | 4,984 | $17K | Form 4 |
| Jan 2, 2026 | Walker Neal CEO · Director | Option | 29,150 | — | Form 4 |
| Jan 2, 2026 | Walker Neal CEO · Director | Other | 9,952 | $29K | Form 4 |
| Dec 31, 2025 | Loerop James Chief Business Officer | Option | 73,750 | — | Form 4 |
| Jan 2, 2026 | Loerop James Chief Business Officer | Option | 18,150 | — | Form 4 |
| Jan 2, 2026 | Loerop James Chief Business Officer | Other | 6,171 | $18K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ACRS 内幕交易
ACRS 内幕交易
Aclaris Therapeutics, Inc.（ACRS）内幕交易数据来源于公司内部人（包括Balthaser Kevin (CFO), Loerop James (Chief Business Officer), Walker Neal (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ACRS内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Aclaris Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ACRS 内幕交易 · 5个问题Aclaris Therapeutics, Inc.（ACRS）的内部人包括高管和董事，如Balthaser Kevin (CFO), Loerop James (Chief Business Officer), Walker Neal (CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026